| Primary information |
|---|
| sequence ID | Seq_2833 |
| Peptide sequence | GLEEELQFSLGSKINVKVGGNS |
| CancerPDF_ID | CancerPDF_ID40, CancerPDF_ID884, CancerPDF_ID1055, CancerPDF_ID8562, CancerPDF_ID9627, |
| PMID | 16896061,19795908,16395409,23667664,21533267 |
| Protein Name | Complement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C3f,Complement C4-B |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO3_HUMAN,CO4B_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum |
| M/Z | 2305.2,769.07,2305.2,2304.2,769.05 |
| Charge | 1,3,1,1,3 |
| Mass (in Da) | 2305.19,NA,NA,2306.58,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID40, CancerPDF_ID884, CancerPDF_ID1055, CancerPDF_ID8562, CancerPDF_ID9627, |
| p-Value | 1.00E-05,NA,7.90E-10,NA,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT,MASCOT |
| Length | 22,22,22,22,22 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer","Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,NA,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively",NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,NA,Independent validation,NA,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA |
| Peptide Atlas | NA |
| IEDB | |